These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25467275)

  • 1. The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease.
    Ghobadifar MA; Kalani N; Gitiforouz M; Mosallanejad Z
    Rev Soc Bras Med Trop; 2014; 47(5):669. PubMed ID: 25467275
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' reply: Vitamins in the treatment of chronic Chagas disease: adjuvant antiparasitary or antioxidant therapy?
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2014; 47(5):670-1. PubMed ID: 25467276
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2013; 46(6):776-8. PubMed ID: 24474023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries for patients. Long-term outcomes of treating nonacute Chagas disease with benznidazole.
    Ann Intern Med; 2006 May; 144(10):I32. PubMed ID: 16702585
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease.
    Guevara AG; Taibi A; Alava J; Guderian RH; Ouaissi A
    Trans R Soc Trop Med Hyg; 1995; 89(4):447-8. PubMed ID: 7570896
    [No Abstract]   [Full Text] [Related]  

  • 6. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission.
    Sosa-Estani S; Cura E; Velazquez E; Yampotis C; Segura EL
    Rev Soc Bras Med Trop; 2009; 42(5):484-7. PubMed ID: 19967227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.
    Viotti R; Vigliano C; Lococo B; Bertocchi G; Petti M; Alvarez MG; Postan M; Armenti A
    Ann Intern Med; 2006 May; 144(10):724-34. PubMed ID: 16702588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].
    Moretti E; Cervetta L; Basso B; Castro I; Santamarina N
    Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shift of excretory-secretory immunogens of Trypanosoma cruzi during human Chagas' disease.
    Jazín EE; Luquetti AO; Rassi A; Frasch AC
    Infect Immun; 1991 Jun; 59(6):2189-91. PubMed ID: 1903775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection.
    Davies C; Simonazzi A; Micheloud JF; Ragone PG; Cid AG; Negrette OS; Bermúdez JM; Parada LA
    J Parasitol; 2020 Jun; 106(3):323-333. PubMed ID: 32369594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criteria of Chagas disease cure.
    Cançado JR
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():331-5. PubMed ID: 10677750
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole.
    Chippaux JP; Clavijo AN; Santalla JA; Postigo JR; Schneider D; Brutus L
    Trop Med Int Health; 2010 Jan; 15(1):87-93. PubMed ID: 19968839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala.
    Brum-Soares L; Cubides JC; Burgos I; Monroy C; Castillo L; González S; Viñas PA; Urrutia PP
    Rev Soc Bras Med Trop; 2016; 49(6):721-727. PubMed ID: 28001219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole.
    Teixeira AR; Córdoba JC; Souto Maior I; Solórzano E
    Am J Trop Med Hyg; 1990 Aug; 43(2):146-58. PubMed ID: 2117856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.